Then, in July, Eli Lilly agreed to acquire AtaiBeckley, a biotechnology company developing psychedelic and psychedelic-derived treatments. It called for trained clinicians, controlled settings, and the same scientific and ethical standards applied to other promising medicines. In an ordinary drug study, neither patients nor investigators are supposed to know who received the active medication and who received the placebo. It also specifies that timely approvals remain for drugs meeting the standards of the Federal Food, Drug, and Cosmetic Act. Large pharmaceutical companies have resources for manufacturing, multicenter trials, regulatory science, and pharmacovigilance that smaller biotechnology firms often lack.